Professor Rob Sutherland AO FAA
Director, The Kinghorn Cancer Centre; Director, Cancer Research Program, Garvan Institute of Medical Research; NHMRC Senior Principal Research Fellow; Conjoint Professor, Faculty of Medicine, The University of New South Wales
Email: r.sutherland 'at' garvan.org.au
Research Group: Prostate Cancer, Steroid Hormone Action, Breast Cancer
Education
B AgrSc, University of Canterbury, New Zealand
M AgrSc, University of Canterbury, New Zealand
PhD, Australian National University, Canberra
Awards and Honours
1994 DSc (Honoris causa) Lincoln University, New Zealand
2000 The Ramaciotti Medal for Excellence in Biomedical Research
2002 Fellow of the Australian Academy of Science
2003 Centenary of Federation Medal
2010 Officer, General Division of the Order of Australia
2010 NSW Premier's Award for Outstanding Cancer Researcher
Publications
Musgrove EA, Caldon CE, Barraclough J et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11(8):533-618.
O'Toole SA, Machalek DA, Shearer RF et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 2011; 71(11):4002-4014.
Roberts CG, Millar EK, O'Toole SA et al. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 2011; 30:3186-3197.
Fedele CG, Ooms LM, Ho M et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci 2010; 51:22231-22236.
Hochgrafe F, Zhang L, O'Toole SA et al. Tyrosine phosphorylation profiling reveals the signalling network characteristics of basal breast cancer cells. Cancer Res 2010; 70:9391-9401.
Hudson TJ, Anderson W, Aretz A et al. International network of cancer genome projects. Nature 2010; 464(7291):993-998.
Biankin AV, Kench JG, Colvin EK et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009; 137(2):558-568.
Chang DK, Johns AL, Merrett ND et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27(17):2855-2862.
Millar EKA, Graham PH, O'Toole SA et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol 2009; 27(28):4701-4708.
Millar EKA, Dean JL, McNeil CM et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene 2009; 28(15):1812-1820.
Musgrove EA, Sutherland RL. Biological determinants of resistance to tamoxifen treatment in breast cancer. Nat Rev Cancer 2009; 9(9):631-643.
Peters AA, Buchanan G, Ricciardelli C et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69(15):6131-6140.
Zhao L, Lee BY, Brown DA et al. Identification of candidate biomarkers of therapeutic response to Docetaxel by proteomic profiling. Cancer Res 2009; 69(19):7696-7703.
Wang Y, Dean JL, Millar EKA et al. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res 2008; 68(14):5628-5638.
Henshall SM, Horvath LG, Quinn DI et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98(19):1420-1424.
